The modulation of miR300 and/or PP2A-activating treatment can trigger LSC apoptosis; thereby, making this TUG1/miR-300/PP2A signaling pathway important for both CML development and treatment [151]. Here, TUG1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.